Journal of Surgery (ISSN: 2575-9760)


Resection of the Primary Tumor in Asymptomatic or Minimally Symptomatic Patients with Stage IV Colorectal Cancer and Unresectable Metastases

Antonio V Sterpetti*

Department of Surgery,University of Rome- Sapienza, Italy 

*Corresponding author: Antonio V Sterpetti, Policlinico Umberto I- Viale del Policlinico 00167 Rome-Italy. Tel: +39649972188; Fax: + 39649972215;

Received Date: 18 September, 2017; Accepted Date: 21 September, 2017; Published Date: 28 September, 2017


Colorectal cancer is a commonly diagnosed cancer. More than 25% of the patients have an initial diagnosis at a Stage IV, with a 5 year overall relative survival of 10-18%[1-3].Simultaneous resection of the primary tumorand of all metastases can be conceptually curative; however, more than 80% of the patients presents with unresectable colorectal metastases.Primary tumor resectionis an accepted therapeutic option in patients with major symptoms related toa Stage IV colorectal cancer, with unresectable metastases. Controversies exist about the opportunity of primary tumor resection in patients with no symptoms or mild symptoms. The basic philosophy for resection is that about 20% of the patients initially asymptomatic will develop major symptoms (obstruction, bleeding, perforation), requiring emergency surgery. 

New chemotherapeuticagents have been introduced into clinical practice, including oxalplatin, bevacizumab, capecitabine, regorafenib.These new drugs, alone or in combination with fluorouracil and leucovorin,have been shown to prolong survival and to reduce the advent of major complications in patients with Stage IV colorectal cancer and unresectable metastases[4-8]In the same period, endoscopic placement of self-expanding metallic stent has been slowly accepted in the clinicalpractice [3].Complications after endoscopic stenting have been reduced with increasing experience, and stentinghas been demonstrated to be avalid alternative in selected patients with Stage IV colorectal cancer and unresectable metastases[9-12].Several retrospective studies have been reported.All studies showbetter results after primary resection of the tumor[13-18]reviewed the results of26 studies which included 43,903 patients. Using random subgroup analysis, they tried to overcome the clinical and anatomic differences between subgroups.Patients receiving primary tumor resection plus chemotherapy/radiotherapy had longer overall survival. In 3 studies, details about Progression Free Survivalwere described.Random subgroup analysis showed longer Progression Free Survival in patients who had primary tumor resection. 

All the reported retrospective studies conclude that there is the possibility of significant selection bias, therefore caution should be used in analyzing results[19]tried to overcome the possibility of selection biases, using a propensity matching score. They analyzed the data of 10,371patients with Stage IV colorectal cancer and unresectbale metastases from the Netherlands Cancer Registry (2008-2011):2,746 patients who had primary tumor resection. Using propensity matching score theyfound that patients who had primary tumor resection had a median survival of 17,2 months, while those who did not have surgery had a median survival of 11.5 months. In Cox regression analysis, primary tumor resection was associated with longer survival. In this study several important data were not reported, including T and histology of the primarytumor[20]using the same type of statistical analysis, did not find any influence of primary tumor resection in patients with stage IV colorectal cancer and unresectable metastases.

There are also many conceptual differences between patients, in the way they could respond to targeted therapy [21-24] (Figure 1-3).

The resection of the primary tumor has several theoretical advantages. 

·         Cells of the primary tumor produce high quantities of VEGF and EGF, which also can be found in the blood circulation [25]. These growth factors could have a stimulatory action on the liver metastases. Primary tumor resection eliminates the source of a potential continuous growth stimulus for liver metastases.

·         The high levels of growth factors in the primary tumor could neutralize the majority of the targeted therapy, which will result unable to act on liver metastases

·         Liver metastases, can differentiate from the primary tumor, with higher possibility of being sensitive to the biological drugs. 

To these theoretical advantages, we should add the negative effect on the immunological system of surgery per se.Several multicenterprospective trials are being conducted in Germany, Korea and Spain, to analyze the importance of resection in these groups of patients. These studies probably will helpto clarify some of the questions about this matter [26].Patients with Stage IV colorectal cancer and unresectable metastases represent a significant heterogenous group of patients. In the absence of clear guidelines, the treatment should be based on clinical judgment. An easy surgical act in a relatively young patient in acceptable general conditions seems advisable.Many questions remain about the association of chemotherapy in this scenario and which type of chemotherapy. There is the possibility of an aggressive chemotherapeutic regimen in patients with good conditions, with inevitable reduced quality of life.All these considerations should be taken into account. A close collaboration among surgeons, oncologistsis essential, considering each patient in his individuality with his own needs and expectations. 

Figure 1: Schematic Drawing Representing the Inhibitory Action of Bevacizumab on VEGF.

Figure 2: Schematic Drawing Representing the Inhibitory Action of Cetuximab on EGF.

Figure 3: Schematic Representation of The Action of VEGF And EGF In Promoting Cancer Cell Growth and Diffusion.


1.       Siegel R, Desantis C, Jemal (2014) Colorectal cancer statistics CA Cancer J Clin 64:104-117.

2.       Benson AB III, ArnolettiJP, Bekaii-Saab T, Chan E, Chen YJ, et al. (2011) National Comprehensive Cancer Network: Colon Cancer J Natl ComprCancNetw 9: 1238-1290.

3.       Lamazza A, Fiori E, Sterpetti AV,Schillaci A, Scoglio D, et al. (2014) Self expandanble metal stents in the treatmjent of benign anastomotic stricture after rectal resection for cancer Colorectal Dis 16: 150-153.

4.       Cook AD, Single R, McCahill LE (2005) Surgical resection of primary tumors in patients who presents with Stage IV colorectal cancer; an analysis of surveillance, epidemiology, and end results data 1988-2000 Ann SurgOncol 12:637-645.

5.       Poultsides GA, Servais EL, Saltz LB,Patil S, Kemeny NE, et al. (2009) Outcome of primary tumor in patients with synchronous Stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment JClinOncol 27: 3379-3384.

6.       McCahill LE, Yothers G, Sharif S,Petrelli NJ, Lai LL, et al. (2012) Primary mFOLFOX6 plus bevacizumabwithout resection of the primary tumor for patients presenting withsurgically unresectable metastaticcolon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10 J ClinOncol 30:3223-3228.

7.       Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, et al. (2008) K-RAS mutations and benefit from cetuximab in advanced colorectal cancer N Engl J Med 359:1757-1765.

8.       Hu CY, Bailey CE,YouYN,Skibber JM, Rodriguez-Bigas MA, et al. (2015) Time trend analysis of primary tumor resection for stage IV colorectal cancer. Less surgery, improved survival JAMA Surg 150:245-251.

9.       Lamazza A, Fiori E, Schillaci A, Sterpetti AV (2013) A new technique for self-expandable metalstent placement in patients with colorectal obstruction SurgEndosc27: 1045-1048.

10.    Lamazza A, Fiori E, Schillaci A, Sterpetti AV, Lezoche E (2014) Treatment of anastomosis stenosis and leakage after colorectal resection with self-expanadable metal stents Am J Surg 208: 465-469.

11.    Lamazza A, Sterpetti AV, De Cesare A,Schillaci A, Antoniozzi A, et al. (2015)Endoscopic placement ofself-expanding stents in patients with symptomatic leakage after colorectal resection for cancer: Long term results Endoscopy 47: 270-272.

12.    Lamazza A, DeMasi E, Fiori E,Scoglio D, Sterpetti AV, et al. (2013) Self expanding metal stents for treatment of anastomotic complication after colorectal resection Endoscopy 45: 493-495.

13.    Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, et al. (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III studyJClinOncol 26:2013-2019.

14.    Hurwitz H, Tebbutt NC, Kabbinavar F,Giantonio BJ, Guan ZZ, et al. (2013) Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials Oncologist 18:1004-1012.

15.    Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, et al. (2012) Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer Nature 486:532-536.

16.    Ahmed S, Fields A, Pahwa P,Selliah Chandra-Kanthan, Adnan Zaidi, et al. (2015) Surgical resection of primary tumor in asymptomatic or minimally symptomatic patients with Stage IV colorectal cancer. A Canadian province experience Clin Colorectal Canc 14:41-47.

17.    Faron M, Pignon JP, Malka D,Douillard JY, Adenis A,et al. (2015) Is primary tumor resection associated with survivalimprovement in patients with colorectal cancer and unresectable synchronous metastases? A pooled analysis ofindividual data from four randomized trials Eur J Cancer 50:156-166.

18.    Lee KC, Ou CY, Hu WH,Liu CC, Chen HH (2016) Meta-analysis of outcomes of patients with Stage IV colorectal cancer managed with chemotherapy/radiochemotherapy with and without primary tumor resection Onco Target an Therapy 9: 7059-7069.

19.    Lam-Boer J, Van der Geest LG, Verhoef G,Elferink ME, Koopman M, et al. (2016) Palliative resection of the primary tumor is associated with improved overall survival in incurableStage IV colorectal cancer. A nation-wide population-based propensity-score adjusted study in the Netherlands Int J Cancer 132: 2082-2094.

20.    Alawadi Z, Phatak Z, Hu CY,Bailey CE, You YN, et al. (2017) Comparative effectiveness of primary tumor resection in patients with Stage IV colorectal cxancer Cancer 123: 1124-1133.

21.    Geile PK, Yothers G, Taniyama Y,Tanaka N, Gavin P, et al. (2013) Defective mismatch repair and benefit form bevacizumab for colon cancer: Findings from NSABP C-08 J Natl CancerInst 105:989-992.

22.    deGramont A, Van Cutsem E, Schmoll HJ,Tabernero J, Clarke S, et al. (2012) Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial Lancet Oncol13:1225-1233.

23.    Kerr RS, Love S, Segelov E,Elaine Johnstone, Beverly Falcon, et al. (2016) Adjuvant capecitabine pls bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label randomized phase 3 trial Lancet Oncolo 17:1543-1557.

24.    Diaz LA, Williams RT, WU j,Isaac Kinde, J. Randolph Hecht, et al. (2012) The molecular evolution of acquired resistance to targeted EGFR blockade n colorectal cancer Nature 486:537-540.

25.    Marisi G, Scarpi E, Passardi A, Oriana Nanni, Angela Ragazzini, et al. (2017) Circulating VEGF and e-NOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab Scientific Reports 7:1293.

26.    Soreide K (2016) Resection of asymptomatic primary tumor in unresectable Stage IV colorectal cancer: time to move on from propensity matched scores to randomized controlled studies Int J Cancer 139:1927-1929.